دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Awareness campaigns and cancer screening
doi : 10.1016/S1470-2045(22)00340-0
Volume 23, Issue 7, July 2022, Page 829
Immunotherapy in colorectal cancer: an unmet need deserving of change
ElenaElezabIosuneBaraibara
Stereotactic radiosurgery for patients with small-cell lung cancer brain metastases
StefanRiekenab
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
Sjoukje FOostingaAstrid A Mvan der VeldtdeRudolf S NFehrmannaCorine HGeurtsvanKesselfRob Svan BinnendijkhAnne-Marie CDingemansgEgbert FSmitiT Jeroen NHiltermannbGercoden HartoghMathildaJalvingaTatjana TWestphallArkajyotiBhattacharyaaFayede WiltfAnnemarieBoermacLisannevan ZijljGuus FRimmelzwaanmPiaKvistborgkCecile A C Mvan Elshn…Elisabeth G Ede Vriesa
When competition is not enough: leveraging US policies to curb oral anticancer drug costs
Kunal CPotnisaScott FHuntingtonab
Multi-cancer early detection tests for cancer screening: a behavioural science perspective
Laura A VMarlowaNinianSchmeising-BarnesaKateBrainbSueDuncombeaKathryn ARobbcThomasRounddSaskia CSandersoneJoWallera
Efficacy in randomised trials: the time matters
AlessandroOttaianoaMariachiaraSantorsolaaMicheleCaragliabGuglielmoNastia
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations
ShuvadeepGangulyaAjayGogiaa
Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations – Authors' reply
RebeccaKristeleitaAmit MOzab
How molecularly similar are primary and metastatic tissues in renal cell carcinoma?
Burcu UlaşKahyaabOsmanSütcüoğluabNuriyeÖzdemirabOzanYazıcıab
How molecularly similar are primary and metastatic tissues in renal cell carcinoma? – Authors’ reply
Yann-AlexandreVanoacdeRézaElaidibLetuanPhanbMaximeMeylandWolf HermanFridmandCatherineSautès-FridmandStéphaneOudardaceBIONIKK co-investigators
Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma
Yann-AlexandreVanoabdRézaElaidicLetuanPhancWolf HermanFridmanbCatherineSautès-FridmanbStéphaneOudardbdBIONIKK co-investigators
Amended bipartisan bill to expand clinical trial options for paediatric cancer in the USA
ManjulikaDas
Conflict in Tigray impeding basic care for patients with cancer
MunyaradziMakoni
Patients with cancer in Louisiana denied fertility preservation cover
ElizabethGourd
Centers for Disease Control and Prevention invest in cancer prevention programmes
ManjulikaDas
Radiotherapy in conflict: lessons from Ukraine
PatriciaPriceabRichardSullivancMykolaZubarevdRuslanZelinskyief
Should chemoradiotherapy be standard to maximise cure in localised gastro-oesophageal cancer?
John VReynoldsDarrenCowzerYelena YJanjigian
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Sacha JHowellFRCPa†AngelaCasbardMScb†MargheritaCarucciPhDbKateIngarfieldPhDbProfRachelButlerFRCPathcSianMorganFRCPathdMagdalenaMeissnerMRCPbCatherineBaleFRCPePavelBezecnyMDfSarahMoonBM BChgProfChrisTwelvesMDhRamachandranVenkitaramanFRCRiSimonWatersFRCPjElza Cde BruinPhDkGaiaSchiavonMD PhDkAndrewFoxleyBAkRobert HJonesFRCPl
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
David JPinatoPhDabJuanAguilar-CompanyMDegDanielaFerrantePhDdGeorginaHanburyMBChBaMarkBowerPhDhRamonSalazarPhDiOriolMirallasMDeAnnaSuredaPhDjAndreaPlajaMDkMarcCucurullMDkRicardMesiaMDkSarahTownsendlAmandaJacksonRNlAlessiaDalla PriaMDhThomasNewsom-DavisPhDhJasmineHandfordMScmAilsaSita-LumsdenPhDoEleanorApthorpBScn…FannyPommeret
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
CarlottaAntoniottiMDabDanieleRossiniMDabFilippoPietrantonioMDdAurélieCatteauPhDeLisaSalvatorePhDfgSaraLonardiMDhIsabelleBoquetPhDeStefanoTamberiPhDjFedericaMarmorinoMDabRobertoMorettoMDaMargheritaAmbrosiniMDdEmilianoTamburiniMDkProfGiampaoloTortoraPhDfgAlessandroPassardiMDlFrancescaBergamoMDiAlboukadelKassambaraPhDeThomasSbarratoPhDeFedericaMoranoMDd…ProfChiaraCremoliniPhDab
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial
ProfRobert JMotzerMDaThomasPowlesMDbMauricioBurottoMDcBernardEscudierMDdMaria TBourlonMDeAmishi YShahMDfCristinaSuárezMDgAlketaHamzajMDhCamilloPortaMDijChristopher MHockingMBBSkElizabeth RKesslerMDlHowardGurneyMBBSmProfYoshihikoTomitaMDnProfJensBedkeMDoJoshuaZhangMDpBurcinSimsekPhDqChristianScheffoldMDrAndrea BApoloMDsProfToni KChoueiriMDt
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
NeerajAgarwalMDaBradleyMcGregorMDbBenjamin LMaughanMDaTanya BDorffMDcProfWilliamKellyDOdBrunoFangMDeRana RMcKayMDfParminderSinghMDgProfLancePagliaroMDhRobertDreicerMDiProfSandySrinivasMDjYohannLoriotMDkUlkaVaishampayanMDlmSanjayGoelMDnoDominicCurranMBChBpAshokPanneerselvamPhDpMartinSchwickartPhDpToni KChoueiriMDb*SumantaPalMDc*
MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study
BehfarEhdaieMDaClare MTempanyMDdFordHollandMScbDaniel DSjobergMScbAdam SKibelMDeQuoc-DienTrinhMDeJeremy CDurackMDcfOguzAkinMDcAndrew JVickersPhDbPeter TScardinoMDaDanSperlingMDgJeffrey Y CWongMDhBertramYuhMDiDavid AWoodrumMDjLance AMynderseMDkSteven SRamanMDlAllan JPantuckMDmMarc HSchiffmanMDn…PejmanGhanouniMDqâ€
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
Andrew RClampPhDaElizabeth CJamesMScbProfIain AMcNeishPhDcAndrewDeanMBChBdProfJae-WonKimPhDeDearbhaile MO'DonnellMDfDoloresGallardo-RinconMDgProfSarahBlagdenPhDhProfJamesBrentonFRCPiProfTim JPerrenMDjSudhaSundarMPhilkRosemaryLordPhDlGrahamDarkMBBSmProfMarciaHallPhDnSusanaBanerjeePhDoRosalind MGlasspoolPhDpC LouiseHannaFRCRqSarahWilliamsMBChBr…ProfJonathan ALedermannMDaa
Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis
KarolinaGaebeBMathaAlyssa YLiBAaAmyParkBScaAmbicaParmarMDcBenjamin HLokMDaeProfArjunSahgalMDadKelvin K WChanMD PhDacAnders WEricksonBScbSunitDasMD PhDaf
Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial
Jaimie ZShingPhDa*ShangyingHuMDac*RolandoHerreroPhDdeAllanHildesheimPhDaCarolinaPorrasMScdJoshua NSampsonPhDaJohnSchusslerBSfJohn TSchillerPhDbDouglas RLowyMDbMónica SSierraPhDaLorettoCarvajalMDadAimée RKreimerPhDa
Accuracy and effectiveness of HPV mRNA testing in cervical cancer screening: a systematic review and meta-analysis
ProfMarcArbynPhDabMarieSimonMDcSilviade SanjoséPhDdeMegan AClarkePhDdProfMarioPoljakPhDfRemilaRezhakePhDgProfJohannesBerkhofPhDhVictoriaNyagaPhDaMuratGultekinMDiProfKarenCanfellPhDjNicolasWentzensenPhDd
Systemic considerations for the surgical treatment of spinal metastatic disease: a scoping literature review
Mark AMacLeanMDaCharles JTouchetteMDbMiltiadisGeorgiopoulosMDcTristanBrunette-ClémentMDdFahad HAbduljabbarMBBSeProfChristopher PAmesMDfProfChetanBettegowdaMDgRaphaeleCharest-MorinMDhNicolasDeaMDhProfMichael GFehlingsMDiProfZiya LGokaslanMDkC RoryGoodwinMDlIlyaLauferMDmCordulaNetzerMDnProfLaurence DRhinesMDoProfArjunSahgalMDjJohn HShinMDpProfDaniel MSciubbaMDq…Michael HWeberMDc
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
ProfDominiqueFargeMD PhDacd†CorinneFrereMD PhDe†Jean MConnorsMD PhDfProfAlok AKhoranaMDgProfAjayKakkarMBBS PhDhiProfCihanAyMD PhDjProfAndresMuñozMDkProfBenjaminBrennerMDlPedro HPrataMDbDialinaBrilhanteMDmDarkoAnticMDnPatriciaCasaisMDoProfMarÃa CeciliaGuillermo EspositoMDpProfTakayukiIkezoeMDqSyed AAbutalibMDrProfLuis AMeillon-GarcÃaMDsProfHenriBounameauxMDtProfIngridPabingerMD PhDj…ChikaoYasuda
Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective
ProfEnriqueTeranPhDaHenryGomezMDbDamianHannoisMDcMauricioLemaMDdWilliamMantillaMDeMarianaRico-RestrepoMDfElizabethMcElweeMPHgNoeCastro SanchezPhDhNataliaValdiviesoMDiManuel AntonioEspinozaPhDj
Sacral insufficiency fracture after treatment for cervical cancer
John MMathewMDaAswinKumarMDaNithyaPuthiyedathMDb
